Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$9.90 - $27.20
Next Earnings Date
May 14 2025
Next Earnings Date
May 14 2025
Latest price
Market Cap | $1.10B |
EV | $595.28M |
Shares Outstanding | 81.51M |
Beta | 0.86 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $39.69 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | -53.30% |
EPS | 22.80% |
Operating Cash Flow | -62.10% |
Free Cash Flow | -62.20% |
Revenue | 909.40% |
EPS | 8.40% |
Operating Cash Flow | -3.40% |
Free Cash Flow | 9.60% |
Gross Margin 2025E | 100.00% |
Net Profit Margin 2025E | -209524.87% |
ROE 2025E | - |
ROCE 2024 | -58.07% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Viridian Therapeutics, Inc.
VRDN
Sector
Healthcare
Industry
Biotechnology
CEO
Mahoney, Stephen
Employees
143
Website
www.viridiantherapeutics.comIPO Date
2014-06-18
Headquarters
221 Crescent Street, Suite 401, Waltham, Massachusetts, 02453, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved